Visit our site often to see news day in and day out on medicine, patient support, our effective clinical center for the obese
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
CVD manifestations in T2D include ischemic heart disease, heart failure, stroke, coronary artery disease, and peripheral artery disease, collectively contributing to mortality in over 50% of affected individuals [6]
J Clin Invest (2022) 132:e158449
Set hydration timers if necessary
It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it stimulates insulin secretion and inhibits glucagon release in a glucose-dependent manner
